Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415484 | 0.95 | SMN1; SMN2 (0.49) | CNR2CNR1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL12415487 | 0.88 | ALDH1A1 (0.37) | CNR2CNR1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL12415479 | 0.81 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL12415492 | 0.77 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL12415510 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL18098039 | 0.74 | USP2 (0.41) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL12415494 | 0.74 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL12415486 | 0.73 | PIK3CD (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP19A1 | |
| SCHEMBL11594277 | 0.73 | ALDH1A1 (0.83) | CNR2CNR1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10625208 | 0.72 | MEN1 (0.83) | CNR2CNR1ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | RCSD1, RRP12, TIAM1 | CNR2 3475/4885CNR1 3446/4885ALDH1A1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.